Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Share this content:
This study used a Markov decision-analytic model to analyze cost-effectiveness between the 2 drug regimens that considered differences in cost and in QALYs.
This study used a Markov decision-analytic model to analyze cost-effectiveness between the 2 drug regimens that considered differences in cost and in QALYs.

Brentuximab vedotin has shown efficacy in lowering risk of progression of advanced Hodgkin lymphoma as a first-line treatment in adults, but it may not be cost-effective, according to a study published in the Journal of Clinical Oncology.

The recent ECHELON-1 clinical trial had compared therapy consisting of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (AVD+BV) vs standard chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in adults with newly diagnosed stage III or IV Hodgkin lymphoma. In that trial, AVD+BV showed a 4.9% improvement in modified progression-free survival at 2 years vs ABVD. AVD+BV also lacks the risk of pulmonary toxicity associated with bleomycin.

The new study used a Markov decision-analytic model to analyze cost-effectiveness between the 2 drug regimens that considered differences in cost and in quality-adjusted life-years (QALYs).

AVD+BV delivered an estimated enhancement in QALYs of 0.56 over ABVD in first-line treatment for advanced Hodgkin lymphoma. However, costs were considerably higher for AVD+BV, with a lifetime direct healthcare cost of $361,137 compared with $184,291 for ABVD.

The incremental cost-effectiveness ratio (ICER) per QALY for AVD+BV vs ABVD in first-line Hodgkin lymphoma treatment was estimated to be $317,254 (95% CI, $159,408-$903,061).

The authors also modeled indication-specific pricing, which showed the acquisition cost of including brentuximab vedotin in first-line treatment of Hodgkin lymphoma would have to be lowered by 56% or 73% to bring the ICER down to $150,000 or $100,000, respectively, per QALY. 

Although the use of brentuximab vedotin has shown clinical benefit in place of bleomycin in first-line chemotherapy for Hodgkin lymphoma, the study authors consider this to be currently not cost-effective and recommended indication-based pricing of this drug. 

Reference

Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma[published online October 4, 2018]. J Clin Oncol. doi: 10.1200/JCO.18.00122

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs